On October 5, 2023, Annette Matthies, Ph.D., Chief Business Officer of Elicio Therapeutics, Inc. (the ?Company?) was terminated without cause, effective as of the same date (the ?Separation Date?).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.85 USD | -0.11% | -11.94% | +6.12% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+6.12% | 85.96M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- ELTX Stock
- News Elicio Therapeutics, Inc.
- Elicio Therapeutics, Inc. Announces Resignation of Annette Matthies as Chief Business Officer